April 27th 2022
The FDA recently issued a statement warning the public of the risks and potential false results obtained with noninvasive prenatal screening tests, noting that inappropriate usage and interpretation has resulted in improper medical decisions.
September 30th 2021
Noninvasive prenatal screening for single-gene disordersSeptember 8th 2021
A study in the journal Ultrasound in Obstetrics & Gynecology1 has found that noninvasive prenatal testing (NIPT) can help in the early detection of a set of single gene disorders (SGDs), especially in the presence of either abnormal ultrasound findings or a family history.
Noninvasive prenatal testing and good motherhoodAugust 31st 2021
Pregnant women do not believe that noninvasive prenatal testing (NIPT) is an obligation of responsible motherhood, according to a qualitative study that investigated the impact of NIPT on women's moral beliefs about the meaning of prenatal screening.
NIPT may not be as effective for twin pregnanciesJuly 20th 2021
Clinicians should carefully consider using noninvasive prenatal testing (NIPT) for the screening of chromosomal abnormalities in twin pregnancies because the combined positive predictive value (PPV) is limited and the screening efficiency is not stable, according to a prospective study.
Risk of miscarriage with amniocentesisJuly 19th 2021
Despite the inadvisability of performing early amniocentesis (EA) before 15 gestational weeks due to a high rate of miscarriage, a retrospective cohort study has found no significant difference in the procedure-related risk of miscarriage between EA, at around 14 weeks gestation, and mid-trimester amniocentesis (MA).
Fetal blood group genotype for managing hemolytic disease of fetus and newbornMay 5th 2021
A systematic review and meta-analysis on the benefits of non-invasive prenatal testing (NIPT) for detecting hemolytic disease of fetus and newborn (HDNF) validates routing anti-D prophylaxis.
Whole genome sequencing of cell-free DNA for NIPTMay 5th 2021
An analysis of a large cohort of patients who chose noninvasive prenatal testing (NIPT) as a screening method for fetal trisomy 21, 18, and 13 (T21, T18 and T13) and sex chromosome aneuploidies (SCA) concluded there were extremely high detection rates and exceptionally low false positive rates.
Economic impact of coverage expansion for NIPTApril 15th 2021
Expanding coverage for noninvasive prenatal testing (NIPT) through a performance-based, risk-sharing agreement (PBRSA) resulted in a significant increase in NIPT use, a significant decrease in conventional prenatal screening methods, and a negligible increase in per member per month (PMPM) cost at Harvard Pilgrim Health Care (HPHC) in New England.
Cost of cell-free DNA noninvasive testing for Down syndromeMarch 9th 2021
A public health screening program for Down syndrome in Quebec, Canada, found that cell-free DNA noninvasive prenatal testing (NIPT) could be implemented at the same cost as the current screening program, according to computer simulations.
Expanding scope of noninvasive prenatal testingFebruary 23rd 2021
“Our results can further inform the debate on the future uses of NIPT and future policy of its implementation,” said co-principal investigator Hazar Haidar, PhD, a lecturer in bioethics at Université du Québec à Montréal (UQAM), Montréal, Canada.
Fetal aneuploidy screening with a noninvasive prenatal testFebruary 1st 2021
A population-based register study from the Netherlands has found that the percentage of pregnant women opting for fetal aneuploidy screening reached a high of 45.9% within 1 year after the introduction in 2017 of a noninvasive prenatal test (NIPT) as a first-tier test for all women.